Jong Seok Lee

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang et al. · Journal of Clinical Oncology · 2005 · 775 citations · Full text

Medicine, Oncology, Pharmacology +17

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd et al. · The Lancet Oncology · 2016 · 643 citations

Medicine, Oncology, Pharmacotherapy +9

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

Jake June-Koo Lee, Junehawk Lee, Sehui Kim et al. · Journal of Clinical Oncology · 2017 · 508 citations

Medicine, Genetics, Oncology +17

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn et al. · The Lancet Oncology · 2020 · 413 citations · Full text

Medicine, Oncology, Pharmacology +15